CapsoVision (CV) announced that it has submitted an application to the FDA on November 6, requesting breakthrough device designation to accelerate development of the company’s CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CV: